Posted by Michael Wonder on 13 Jul 2022
Ancora Heart receives breakthrough device designation from FDA for the AccuCinch ventricular restoration system
12 July 2022 - Designation allows for expedited review of transcatheter therapy designed to improve left ventricular structure and function in heart failure patients with reduced ejection fraction
Ancora Heart today announced that the U.S. FDA has granted breakthrough device designation to the AccuCinch Ventricular restoration system.
Currently being evaluated in the CORCINCH-HF pivotal clinical trial, the AccuCinch System is designed to provide a minimally invasive treatment option for patients who have symptomatic heart failure with reduced ejection fraction.
